diff --git a/Concept-paper-2022-02-09.md b/Concept-paper-2022-02-09.md
index b6f5a22..2854dd7 100644
--- a/Concept-paper-2022-02-09.md
+++ b/Concept-paper-2022-02-09.md
@@ -12,6 +12,11 @@ I think I can get two, maybe three, papers out of this:
     - What is the impact of surragate endpoints on phase transition completion? on phase transition?
 
 # Models
+The general benefit I can provide is to:
+
+- Create a straightforward replication/update pathway.
+- Model based on information known at the beginning of the trial.
+    - This might allow me to escape [[EK]]'s markov modeling approach for phase transitions.
 
 ## Phase completion: Joint Probability Estimation (single paper?)
 
@@ -33,7 +38,8 @@ trying to separate out probability of scientific vs market drops.
 
 This would use the IND or similar data to build the list of phase transitions. 
 
-### Design tradeoffs
+### Design tradeoffs.
+
 Some design tradeoffs include
 
 - Normalized or non-normalized transition paths? I'm particularly interested in inclucing mixed-phase paths, i.e. non-normalized paths.